Panacea Biotec announced the launch of world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol , in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step-down wholly-owned subsidiary company viz. Panacea Biotec Germany GmbH, in Germany.

EasyFourPol is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.

EasyFourPol is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic. It achieves the same level of protection as immunized with single-antigen vaccines, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders.

It leads to less vaccination and lesser shots for the child and greater comfort for the parents while ensuring better compliance for healthcare practitioners. Fewer shots also mean time saved for parents and more efficiency at points of vaccination. Additionally, it also helps reduce carbon emissions by reducing the need for vials, syringes, packaging material, and visits to vaccine administration centres.

Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, said, "We are delighted to launch EasyFourPol - another landmark in our innovative and first-in-class combination vaccine portfolio that makes vaccinations easier, benefits the child, parents, and doctors while helping the world meet UN Sustainable Development Goals. We are certain that Indian paediatricians and parents will continue to put their trust in Panacea Biotec to meet evergrowing vaccination needs through innovative solutions."

Panacea Biotec Germany GmbH, a step-down wholly owned subsidiary of Panacea Biotec, is excited to announce registration of Valganciclovir 50 rng/rnl Powder for Oral Solution in Germany. It competes in a €1 million market (as per IQVIA).

Jain further added, "In continuation of our belief to broaden our focus while continuing our therapy focus - Valganciclovir Powder for Oral Solution is a welcome addition to our transplant portfolio in Germany. We look forward to scaling up our operations and continue to build trust with healthcare practitioners as a high-quality sustainable supplier of medicines for transplant care."